Beyond lipid lowering: The anti-hypertensive role of statins

Cardiovascular Drugs and Therapy

Volumn 21, Issue 3, 2007, Pages 161-169

  Chopra, Vineet ^a   Choksi, Palak U ^a   Cavusoglu, Erdal ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Blood pressure lowering; Cholesterol; Endothelium; Pleiotropic; Review; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEVINOLIN; PLACEBO; PRAVASTATIN; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SIMVASTATIN;

ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT INDICATION;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BLOOD PRESSURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; TREATMENT OUTCOME;

EID: 34249311987     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6025-3     Document Type: Review

References (51)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
2. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.
3. Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9.
4. Gotto A, Farmer J. Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003;92:3i-9i.
5. Paradiso-Hardy FL, Gordon WL, Jackevicius CA, Kertland HR, Pearson GJ, Pickering JL, et al. The importance of in-hospital statin therapy for patients with acute coronary syndromes. Pharmacotherapy 2003;23:506-13.
6. Sever P, Dahlof S, Poulter N, Wedel H, Beevers G, Caulfield M, et al for the Ascot Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
7. Waldman A, Kritharides L. The pleiotropic effects of HMG Co-A reductase inhibitors: their role in osteoporosis and dementia. Drugs 2003;63:139-52.
8. Weis M, Heeschen C, Glassford A, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45.
9. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JAF. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-9.
10. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6.
11. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35:549-55.
12. Prasad GV, Ahmed A, Nash M, Zaltsman J. Blood Pressure reduction with HMG-CoA reductase inhibitors in renal transplant patients. Kidney Int 2003;63:360-4.
13. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6.
14. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure and sex differences in myocardial infarction: a 12-year follow-up of the Finnmark Study. Circulation 1996;93:450-6.
15. Julius S. Clinical implications of pathophysiologic changes in the midlife hypertensive patient. Am Heart J 1991;122:886-91.
16. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
17. Rosendorff C. Effects of LDL Cholesterol on vascular function. J Hum Hypertens 2002;16:S26-8.
18. Wassmann S, Laufs U, Baumer A, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7.
19. Libby P. Inflammation in Atherosclerosis. Inflammation in atherosclerosis. Nature 2002;420:868-74.
20. Laufs U. Beyond lipid lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003;58:719-31.
21. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduced endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
22. Tsao PS, Wang B, Buitrago R, Shyy JY-J, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997;96:934-40.
23. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998;44:1799-808.
24. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239-42.
25. Huang Z, Huang PL, Ma J, Ma J, Meng W, Ayata C, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-l-arginine. J Cereb Blood Flow Metab 1996;16:981-7.
26. Huang PL. Disruption of the endothelial nitric oxide synthase gene: effect on vascular response to injury. Am J Cardiol 1998;82:57S-9S.
27. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001;89:415-21.
28. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke Prevention by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998;95:8880-5.
29. Mueck AO, Seeger H, Wallwiener D. Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp Clin Endocrinol Diabetes 2001;109:181-3.
30. Feron O, Dessy C, Desager JP, Balligand J-L. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-8.
31. Darley-Usmar VM, McAndrew J, Patel R, Moellering D, Lincoln TM, Jo H, et al. Nitric oxide, free radicals and cell signalling in cardiovascular disease. Biochem Soc Trans 1997;25:925-9.
32. Li PF, Dietz R, van Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 1997;96:3602-9.
33. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
34. Laufs U, LaFata C, Plutzky J, Liao SK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97:1129-35.
35. Wagner AH, Kohler T, Ruckshloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
36. Harrison DG. Endothelial function and oxidative stress. Clin Cardiol 1997;20:II11-7.
37. Rosendorff C. Pleiotropic effects of statins. In: Kimchi A, editor. Heart disease; new trends in research, diagnosis and treatment. Englewood, NJ: Medimond Medical; 2001. p. 181-186.
38. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:23-33.
39. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
40. Tousoulis D, Antoniades C, Koumallos N, Marinou K, Stefanadi E, Latsios G, et al. Novel therapies targeting vascular endothelium. Endothelium 2006;13:411-21.
41. Williams JK, Sukhova G, Herrington D, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-91.
42. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
43. Van der Wal AC, Backer AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant morphology. Circulation 1994;89:36-44.
44. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: the role of extracellular lipid, macrophages and smooth muscle content. Br Heart J 1993;69:377-81.
45. Borghi C, Bacchelli S, Degli Espositi D. Pressor and metabolic correlates to long-term development of stable hypertension in borderline hypertensive patients. J Hypertens 1997;15:S111.
46. Borghi C, Veronesi M, Bacchelli S, Esposti DD, Cosentino E, Ambrosioni E. Serum cholesterol levels, blood pressure response to stress and incidence of stable hypertension in young subjects with high normal blood pressure. J Hypertens 2004 Feb; 22(2):265-72.
47. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
48. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth cells. Circ Res 1994;74:1141-8.
49. Ng LL, Davies JE, Wojcikiewicz RJ. 3-Hydroxy-3-methyl glutaryl coenzyme A reductase inhibition modules vasopressin-stimulated Ca2+ responses in rat A10 vascular smooth muscle cells. Circ Res 1994;74:173-81.
50. PPP Project Investigators. Design, rationale and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project: a combined analysis of three large scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995;76:899-905.
51. Pitt B, Waters D, Brown VW, van Boven AJ, Schwartz L, Title LM, Eisenberg D, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-6.